Estudios de Perfil Metabolico de Peptidos
Categorías: Metodología de Investigación, Información General
El perfil metabolico describe como se degradan los peptidos en el organismo. Identificar metabolitos es esencial para seguridad y eficacia.
Resumen Simplificado
Metabolismo de peptidos involucra proteolisis; metabolitos activos deben caracterizarse para safety assessment.
Metabolismo de peptidos
Peptidos se metabolizan extensamente. Principal mecanismo. Proteolysis. Enzymatic cleavage. Peptide bonds hydrolysis. Enzimas involucradas. Exopeptidases. N-terminal. Aminopeptidases. Remove amino acids sequentially. C-terminal. Carboxypeptidases. Endopeptidases. Internal cleavage. Trypsin. Basic residues. Arg, Lys. Chymotrypsin. Aromatic. Phe, Tyr, Trp. Elastase. Small aliphatic. Ala, Gly, Val. Specific peptidases. DPP-4. Dipeptidyl peptidase-4. GLP-1 target. NEP. Neprilysin. Multiple substrates. ACE. Angiotensin-converting enzyme. Cathepsins. Lysosomal. Intracellular degradation. Ubiquitin-proteasome. Larger peptides/proteins. Metabolismo determina half-life. Clearance rate. Active metabolite potential. Safety profile.
Identificacion de metabolitos
Metabolite identification es sistematica. In vitro systems. Plasma. Blood. Liver microsomes. S9 fraction. Hepatocytes. Kidney homogenate. Intestinal enzymes. In vivo samples. Plasma. Urine. Bile. Feces. Tissues. Analytical methods. LC-MS/MS. Primary tool. High resolution MS. Exact mass. MS/MS fragmentation. Structure elucidation. Radiolabeled studies. 14C or 3H. Mass balance. Metabolite tracking. Clearance routes. Metabolite profiling. Major metabolites. Greater than 10% exposure. Minor metabolites. Less than 10%. Identification levels. Level 1. Confirmed structure. Reference standard. Level 2. Probable structure. MS/MS match. Level 3. Tentative structure. Reasonable hypothesis. Level 4. Unknown. Molecular formula only. Metabolite ID informa mechanism. Predicts in vivo behavior. Safety implications.
Metabolitos activos
Active metabolites importan. Pharmacological activity. Similar to parent. Different from parent. Novel target. Safety implications. Different toxicity. Longer duration. Accumulation. Examples. N-terminal truncations. May retain activity. C-terminal modifications. Activity changes. Isomerization. Asp isomerization. May alter activity. Oxidation products. Some retain activity. Assessment required. Activity testing. Receptor binding. Functional assays. Cell-based. PK/PD relationship. Metabolite contributes to effect. MIST guidance. ICH M3(R2). Metabolites in safety testing. Greater than 10% of systemic exposure. Need qualification. Disproportionate metabolites. Higher in human than animal. Toxicity testing needed. Active metabolites pueden. Extend effect duration. Cause unexpected effects. Require dose adjustment.
Estudios in vitro de metabolismo
In vitro studies predicen in vivo. Plasma stability. Incubate with plasma. Time course. 0, 15, 30, 60, 120 min. Temperature 37C. Half-life estimation. Species comparison. Human vs animal. Selection relevant species. Liver microsomes. Phase I metabolism. Oxidation. Hydrolysis. S9 fraction. Phase I + Phase II. Hepatocytes. Full metabolic capacity. Phase I + Phase II + transporters. Cryopreserved hepatocytes. Fresh hepatocytes. Intrinsic clearance. Clint = 0.693 / t1/2. Scaling to in vivo. Well-stirred model. Hepatic clearance prediction. Metabolic soft spots identification. Unstable bonds. Modification targets. Enzyme phenotyping. Which enzymes involved. Specific inhibitors. Recombinant enzymes. CYP. Non-CYP. DDI prediction. In vitro data guides in vivo design. Reduces animal use. Early decision-making.
Estudios in vivo de metabolismo
In vivo studies confirm metabolism. Nonclinical species. Rodent. Non-rodent. Toxicology species. Clinical studies. Healthy volunteers. Patients. Sample collection. Plasma. Serial sampling. Urine. Complete collection. Bile. Bile duct cannulated animals. Feces. Mass balance. Tissues. Distribution. Timepoints. Early and late. Capture metabolite profile. Analysis. Quantitative. Parent and metabolites. Qualitative. Metabolite profiling. Radiolabeled ADME. Total radioactivity. Recovery. Pathways. Mass balance study. Single dose. 14C-labeled peptide. Collection until recovery. 90%+ target. Excretion routes. Urine vs feces. Biliary excretion. Persistence. Long-lived metabolites. In vivo metabolism studies are confirmatory. Validate in vitro predictions. Clinical relevance established.
Implicaciones para desarrollo
Metabolism data guides development. Species selection. Relevant metabolism. Human-like profile. NOAEL applicability. Safety monitoring. Metabolite-specific. Active metabolites. Biomarkers. Dosing recommendations. Accumulation risk. Renal impairment. Active metabolite clearance. Drug interactions. CYP involvement. Peptidase competition. Labeling. Metabolic pathways. Active metabolites. Warnings. Special populations. Formulation optimization. Stabilize against degradation. Modify cleavage sites. D-amino acids. Cyclization. Peptidase inhibitors. Half-life extension. PEGylation. Fc fusion. Albumin binding. Metabolism data is essential. Informs multiple decisions. Regulatory requirement. Safety-critical.
Hallazgos Clave
- Proteolisis por exopeptidasas y endopeptidasas es el mecanismo principal de metabolismo
- LC-MS/MS con high-resolution MS identifica estructuras de metabolitos
- Metabolitos activos mayores a 10% de exposicion requieren caracterizacion de seguridad
- Estudios in vitro (plasma, microsomas, hepatocitos) predicen clearance in vivo
- Estudios radiolabeled establecen mass balance y rutas de excrecion
- Metabolismo informa species selection, DDI risk, y optimizacion de half-life
Más artículos en Metodología de Investigación
Más artículos en Información General
Artículos relacionados
Términos del glosario
Preguntas frecuentes
- Que enzimas metabolizan peptidos principalmente?
- Exopeptidasas: aminopeptidasas (N-terminal), carboxipeptidasas (C-terminal). Endopeptidasas: tripsina (Arg, Lys), quimotripsina (aromaticos), elastasa (pequenos alifaticos). Peptidasas especificas: DPP-4, NEP, ACE. Proteasoma ubiquitina para peptidos grandes.
- Cuando un metabolito requiere safety testing?
- Segun ICH M3(R2) y MIST guidance: metabolitos con exposicion mayor a 10% del parent en humanos, o metabolitos disproportionately higher en humanos que en animales toxicology species. Requiere cualificacion toxicologica.
- Como se predice el clearance hepatico desde in vitro?
- Medir intrinsic clearance (Clint) en hepatocitos o microsomas. Usar well-stirred model: Clh = (Qh x Clint) / (Qh + Clint), donde Qh es hepatic blood flow. Scaling factors aplicados. Prediccion cualitativa mas que cuantitativa.
- Que es un estudio de mass balance?
- Administracion de peptido radiolabeled (14C o 3H) seguida de coleccion completa de excreta hasta recovery mayor a 90%. Determina rutas de excrecion (urinaria vs fecal/biliar), identificacion de metabolitos principales, y clearance total del sistema.